Related references
Note: Only part of the references are listed.Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
Aleix Prat et al.
CLINICAL CANCER RESEARCH (2014)
A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers
B. Morancho et al.
ONCOGENE (2013)
HER2 Therapy - An Abundance of Riches
William J. Gradishar
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
Peter A. Fasching et al.
BMC CANCER (2011)
Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study
S. Loibl et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Major Role of p95/611-CTF, a Carboxy-Terminal Fragment of HER2, in the Down-modulation of the Estrogen Receptor in HER2-Positive Breast Cancers
Josep Lluis Parra-Palau et al.
CANCER RESEARCH (2010)
Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients
Jeff Sperinde et al.
CLINICAL CANCER RESEARCH (2010)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis
Kim Pedersen et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
M. Scaltriti et al.
ONCOGENE (2009)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice
O Piloto et al.
CANCER RESEARCH (2005)
Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2
R Gennari et al.
CLINICAL CANCER RESEARCH (2004)
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer
MD Pegram et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)